Mark Womack is an Oncology physician affiliated with Centennial Medical Center. OpenAlex indexes 18 publications with 776 citations (h-index 4).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
605 Glenwood Drive
Suite 200
Chattanooga, TN 374041130
Telephone
423-698-1844Registry record last updated 28 Jan 2013.
Industry payments
12 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Aveo Pharmaceuticals, Inc.Program year20252 payments
- Novartis Pharmaceuticals CorporationProgram year20252 payments
- ABBVIE INC.Program year20252 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
56.7%Platinum-based Drug33.5%Oxaliplatin99%Carboplatin1%Part B, office-administered≥15 patientsCD38-directed Cytolytic Antibody21.2%Daratumumab100%Part B, office-administered≥11 patients+ 12 more classes in this area
Blood & clotting
30.2%Erythropoiesis-stimulating Agent26.5%Darbepoetin alfa100%Part B, office-administered≥25 patientsIron, parenteral preparations3.5%Ferric derisomaltose100%Part B, office-administered≥27 patients+ 1 more class in this area
Sensory organs
4.8%Corticosteroid4.8%Dexamethasone sodium phosphate98%Dexamethasone2%Hydrocortisone0%Part D + Part B<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Results from a phase 2 study of triplet blockade of the IL-27, PD-(L)1, and VEGF pathways with casdozokitug (casdozo, SRF388) in combination with atezolizumab (atezo) and bevacizumab (bev) in patients with unresectable, locally advanced, or metastatic hepatocellular carcinoma (uHCC).
Journal of Clinical Oncology
2024
Similar KOLs
Other experts from the same institution or the same specialty.
Navneet Majhail, MD
Centennial Medical Center
Stephen Strickland, MD
Centennial Medical Center
Carl Awh, MD
Centennial Medical Center
Arthur Ulm, MD
Centennial Medical Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”